FSD Pharma Wins Court Judgment Against Former CEO, Dr. Raza Bokhari
FSD Pharma Wins Court Judgment Against Former CEO, Dr. Raza Bokhari
FSD Pharma Inc. (NASDAQ:HUGE)(CSE:HUGE)(FRA:0K9A) ("FSD Pharma"), a biopharmaceutical company dedicated to building a portfolio of innovative assets and biotech solutions to address ailments affecting millions worldwide, today announces that on June 27, 2024, the United States District Court for the Eastern District of Pennsylvania confirmed FSD Pharma, Inc.'s motion for entry of judgment is granted and judgment is entered in favour of FSD Pharma and against Dr. Raza Bokhari as follows:
FSD Pharma Inc.（纳斯达克股票代码：HUGE）（CSE: HUGE）（FRA: 0K9A）（“FSD Pharma”）是一家致力于建立创新资产和生物技术解决方案组合以解决影响全球数百万人的疾病的生物制药公司，今天宣布，2024年6月27日，美国宾夕法尼亚东区地方法院确认了FSD Pharma, Inc.'的判决动议获得批准，并作出了有利于FSD Pharma和不利于Raza Bokhari博士的判决，判决如下：
- USD $147,301.04, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied.
- CAD $31,912.55, plus interest at a rate of 4% per annum from November 9, 2022 until the date the Judgment is satisfied.
- CAD $15,000.00, plus interest at a rate of 4% per annum from March 1, 2023 until the date the Judgment is satisfied.
- CAD $2,814,229.15, plus interest at a rate of 6% per annum from May 7, 2023 until the date the Judgment is satisfied.
- 147,301.04美元，外加从2022年11月9日起至判决完成之日按每年4％的利率支付的利息。
- 31,912.55加元，外加从2022年11月9日起至判决完成之日起每年4％的利息。
- 15,000.00加元，外加从2023年3月1日起至判决完成之日起每年4％的利息。
- 2,814,229.15加元，外加从2023年5月7日起至判决完成之日按每年6％的利率支付的利息。
In July 2021, FSD's board of directors terminated Dr. Raza Bokhari, its former CEO. Dr. Raza Bokhari filed an arbitration challenging this termination in Ontario, Canada. After years of litigation and an eight-day evidentiary hearing, the Arbitrator ruled against Dr. Raza Bokhari and issued three awards against Dr. Raza Bokhari in favor of FSD, including an award for damages and awards for FSD's fees and costs incurred in the arbitration.
2021 年 7 月，FSD 董事会解雇了其前首席执行官 Raza Bokhari 博哈里博士。Raza Bokhari博士在加拿大安大略省提起仲裁，质疑此次终止。经过多年的诉讼和为期八天的证词听证会，仲裁员对Raza Bokhari博士作出了不利的裁决，并对Raza Bokhari博士做出了三项有利于FSD的裁决，包括一项损害赔偿裁决和对FSD在仲裁中产生的费用和成本的裁决。
FSD's Petition to Confirm the Arbitration Awards was filed May 29, 2024 in the United States District Court for the Eastern District of Pennsylvania under the Convention on the Recognition and Enforcement of Foreign Arbitral Awards, June 10, 1958, 21 U.S.T. 2517, 330 U.N.T.S. 3 (the "New York Convention"). In its opinion granting FSD's Petition, the District Court found that Dr. Raza Bokhari did not offer any valid basis under the New York Convention for the Court to deny enforcement of the arbitration awards against him.
FSD根据1958年6月10日的《承认及执行外国仲裁裁决公约》（21 U.S.T. 2517、330 U.N.T.S. 3）（“纽约公约”），于2024年5月29日向美国宾夕法尼亚东区地方法院提交了确认仲裁裁决的申请。地方法院在批准FSD申请的意见中认定，Raza Bokhari博士没有根据《纽约公约》为法院拒绝执行针对他的仲裁裁决提供任何有效依据。
FSD will pursue all means possible to collect from Dr. Raza Bokhari, current chairman and CEO of Medicus Pharma Ltd.
FSD将尽一切可能向Medicus Pharma Ltd现任董事长兼首席执行官拉扎·博哈里博士收款。